This treatment has been reported to modulate the immune microenvironment by histopathology-based analysis, which showed an increasing number of CD4, CD8, MDSC, and MHC class1 A/B(+) cells and a decrease in the number of regulatory T cells [15–19] The precise mechanism remains unclear because comprehensive analysis to delineate molecular profiles induced by NAT has been limited and is only available in other cancers. Here, BRD2 is linked to cancer.